NCT00436007 - Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen | Biotech Hunter

Enrollment

511

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 15, 2008

Study Completion Date

October 7, 2009

Conditions

Malaria

Interventions

BIOLOGICAL

GSK 257049

GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine

BIOLOGICAL

Tritanrix™ HepB/Hib

GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)

BIOLOGICAL

Rouvax™

Aventis Pasteur's attenuated measles vaccine.

BIOLOGICAL

Stamaril™

Aventis Pasteur's attenuated yellow fever vaccine.

BIOLOGICAL

Polio Sabin™

GSK Biologicals' oral polio virus vaccine

Trial Locations (3)

Unknown

GSK Investigational Site, Lambaréné

GSK Investigational Site, Kintampo

GSK Investigational Site, Dar es Salaam